Veru Inc. [NASDAQ: VERU] slipped around -3.08 points on Wednesday, while shares priced at $11.51 at the close of the session, down -21.11%. The company report on September 7, 2022 that Veru Announces Date for FDA Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome.
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
—Advisory Committee Meeting Scheduled for October 06, 2022—.
Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that FDA’s Pulmonary-Allergy Drugs Advisory Committee will meet to discuss the Company’s request for Emergency Use Authorization of sabizabulin for hospitalized COVID-19 patients at high risk for ARDS. The meeting is scheduled for October 06, 2022.
Veru Inc. stock is now 95.42% up from its year-to-date (YTD) trading value. VERU Stock saw the intraday high of $16.53 and lowest of $10.75 per share. The company’s 52-week high price is 24.55, which means current price is +165.21% above from all time high which was touched on 08/17/22.
Compared to the average trading volume of 8.78M shares, VERU reached a trading volume of 28529756 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Veru Inc. [VERU]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VERU shares is $35.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VERU stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Veru Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 13, 2021. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $12 to $17. The new note on the price target was released on February 09, 2021, representing the official price target for Veru Inc. stock. Previously, the target price had yet another raise from $4.50 to $6, while H.C. Wainwright kept a Buy rating on VERU stock.
The Average True Range (ATR) for Veru Inc. is set at 1.94, with the Price to Sales ratio for VERU stock in the period of the last 12 months amounting to 18.20. The Price to Book ratio for the last quarter was 7.88, with the Price to Cash per share for the same quarter was set at 1.21.
How has VERU stock performed recently?
Veru Inc. [VERU] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -22.65. With this latest performance, VERU shares dropped by -4.56% in over the last four-week period, additionally plugging by 123.93% over the last 6 months – not to mention a rise of 22.06% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VERU stock in for the last two-week period is set at 35.23, with the RSI for the last a single of trading hit 26.44, and the three-weeks RSI is set at 40.25 for Veru Inc. [VERU]. The present Moving Average for the last 50 days of trading for this stock 14.83, while it was recorded at 14.30 for the last single week of trading, and 9.78 for the last 200 days.
Veru Inc. [VERU]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Veru Inc. [VERU] shares currently have an operating margin of -8.88 and a Gross Margin at +78.05. Veru Inc.’s Net Margin is presently recorded at +12.07.
Return on Equity for this stock inclined to 8.11, with Return on Assets sitting at 6.44.
Veru Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.30 and a Current Ratio set at 4.60.
Insider trade positions for Veru Inc. [VERU]
There are presently around $511 million, or 55.70% of VERU stock, in the hands of institutional investors. The top three institutional holders of VERU stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 7,900,000, which is approximately New of the company’s market cap and around 19.48% of the total institutional ownership; GOLDMAN SACHS GROUP INC, holding 4,880,509 shares of the stock with an approximate value of $56.17 million in VERU stocks shares; and TANG CAPITAL MANAGEMENT LLC, currently with $53.3 million in VERU stock with ownership of nearly New of the company’s market capitalization.
Positions in Veru Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 92 institutional holders increased their position in Veru Inc. [NASDAQ:VERU] by around 24,979,384 shares. Additionally, 45 investors decreased positions by around 3,311,074 shares, while 16 investors held positions by with 16,109,361 shares. The mentioned changes placed institutional holdings at 44,399,819 shares, according to the latest SEC report filing. VERU stock had 53 new institutional investments in for a total of 17,397,857 shares, while 21 institutional investors sold positions of 1,547,089 shares during the same period.